Chargement de l’entreprise
Just reported
Q3 2026 results
From Harvard Bioscience's results release of 10 novembre 2026; its quarterly report has since been filed.
Revenue
Actual
22,2M $US
+7,8 % y/y
-2,3 % q/qGuided
21,8M $US
midpoint
Within guide+1,8 %EPS, GAAP
Actual
-0,58 $US
Guided
—
No guide given
Operating income, GAAP
Actual
-1,2M $US
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Harvard Bioscience is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Instruments and Supplies
Graded A or B and worth $2B or more: A first, then the largest.
ISRGIntuitive Surgical, Inc.153,8B $USA+
MDLNMedline Inc.51,9B $USA
ALCAlcon Inc.36,1B $USA
BLCOBausch & Lomb Corp7,5B $USA-
ATRCAtriCure, Inc.2,9B $USA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct. 2026CAGraded C, now A
Construit à partir des documents déposés par Harvard Bioscience, Inc. auprès de la Securities and Exchange Commission (SEC), le gendarme boursier américain. Les chiffres sont tels que publiés, l’historique par action étant retraité sur la base d’actions d’aujourd’hui. Ceci décrit une entreprise — ce n’est pas un conseil en investissement ni une recommandation d’acheter ou de vendre.
